6 health-tech startups to receive Rs 6-Cr sumulative seed funding at IIT Bombay’s ATMAN 3.0

IMT News Desk
IMT News Desk
· 4 min read

ATMAN 3.0 saw strong participation from across India, with 173 HealthTech startups pitching their ideas to TIH IIT Bombay

The Technology Innovation Hub (TIH) at IIT Bombay under the Department of Science and Technology (DST) Govt of India has successfully concluded ATMAN 3.0, its eight-week accelerator programme designed to transform early-stage HealthTech startups into investment-ready businesses. The programme culminated in a Demo Day bringing together investors, healthcare leaders, industry experts, and policymakers to engage with some of the most promising healthcare innovations in the country.

ATMAN 3.0 saw strong participation from across India, with 173 HealthTech startups pitching their ideas to TIH IIT Bombay. Following a rigorous selection and mentoring process, 06 startups emerged as winners from the final cohort of 13 accelerated ventures. On Demo Day, the selected startups were recommended for a total cumulative seed funding amounting to INR 6 crore, with each startup receiving funding support of up to INR 1 Crore, subject to evaluation outcomes.

The shortlisted start-ups are Prezitech Health, (Precigo: a snap-on needle tracking system for ultrasound machines for real-time procedural planning and guidance during high precision medical interventions), Attox Research Laboratories (AMRIT for antimicrobial resistance), Queliz Lifetech (UltraHand, a robotic rehabilitation device), Deepfacts (proRITHM is an AI-powered remote patient monitoring platform using a compact wireless, wearable device to track vitals in real time), MicroHeal, Raycura Medical Technologies (BETTER a rehabilitation device for stroke/paralysis recovery).

Commenting on the successful conclusion of the programme, Kiran Shesh, CEO, Technology Innovation Hub (TIH), IIT Bombay, said, “ATMAN 3.0 is more than an accelerator—it’s a movement to transform bold HealthTech ideas into scalable, world-class solutions. This cohort showcases cutting-edge innovations that reflect India’s rapidly evolving healthcare ecosystem. Bigger, bolder, and future-focussed, ATMAN 3.0 champions sustainability, deep tech, and global competitiveness. With access to top-tier mentorship, domain experts, and strategic investor networks, founders are empowered to create solutions that truly matter. ATMAN 3.0 reaffirms India’s potential to lead global innovation—where every idea ignites change and shapes the future of healthcare.”

Hardik Joshi, COO, Technology Innovation Hub (TIH), IIT Bombay, added, “ATMAN 3.0 accelerator has been designed to provide founders with a comprehensive support framework that goes beyond funding. From technology validation and regulatory guidance to investor readiness and industry connections, the programme enables startups to strengthen their foundations for sustainable growth. The strong participation from investors and ecosystem stakeholders at Demo Day highlights the relevance and readiness of the startups graduating from this cohort.”

The gathering featured a keynote address by Dileep Mangsuli, Chairman, Cancer Treatment Services International and Senior Vice President at Siemens Healthineers, who noted, that the future of healthcare lies in delivering quality care at scale across geographies, with artificial intelligence playing a pivotal role in early screening and prevention. He highlighted that technology adoption must be driven by real-world impact—addressing prevalent healthcare challenges where it makes both clinical and economic sense. Mangsuli outlined three foundational pillars shaping this transformation: patient twinning to enable individualised care pathways, precision therapy to improve outcomes, and the intelligent use of digital data and AI to support informed, timely clinical decision-making.

In addition to startup pitches, Demo Day was marked with discussions on investment trends in healthcare, evolving regulatory frameworks, and emerging technology models shaping the future of the sector. The event also enabled portfolio startups from earlier TIH IIT Bombay programmes to connect with investors for follow-on funding and strategic partnerships. Dedicated networking spaces facilitated meaningful dialogue between founders, investors, and industry stakeholders.

Through ATMAN 3.0, TIH IIT Bombay continues to strengthen its role in bridging the gap between research and commercialisation, reinforcing IIT Bombay’s position as a key enabler of scalable, impact-driven healthcare innovation in India.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk